Adjuvant therapy-related shortening of survival (ATRESS)
Standard
Adjuvant therapy-related shortening of survival (ATRESS) : an underrated phenomenon. / Fink, Michael K; Kleeberg, Ulrich R; Bartels, Stefan.
in: ONCOLOGIST, Jahrgang 20, Nr. 1, 01.2015, S. 88.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Adjuvant therapy-related shortening of survival (ATRESS)
T2 - an underrated phenomenon
AU - Fink, Michael K
AU - Kleeberg, Ulrich R
AU - Bartels, Stefan
PY - 2015/1
Y1 - 2015/1
N2 - Shortening of survival after dissemination following adjuvant treatment is not understood well enough and is difficult to search for in public databases because of the lack of specific search terms. We suggest using the acronym ATRESS, for “adjuvant therapy-related shortening of survival,” in future literature concerning this issue.
AB - Shortening of survival after dissemination following adjuvant treatment is not understood well enough and is difficult to search for in public databases because of the lack of specific search terms. We suggest using the acronym ATRESS, for “adjuvant therapy-related shortening of survival,” in future literature concerning this issue.
KW - Breast Neoplasms/drug therapy
KW - Deoxycytidine/analogs & derivatives
KW - Female
KW - Fluorouracil/analogs & derivatives
KW - Humans
KW - Taxoids/therapeutic use
U2 - 10.1634/theoncologist.2014-0273
DO - 10.1634/theoncologist.2014-0273
M3 - SCORING: Journal article
C2 - 25589500
VL - 20
SP - 88
JO - ONCOLOGIST
JF - ONCOLOGIST
SN - 1083-7159
IS - 1
ER -